Working… Menu
Trial record 52 of 92 for:    Primary Sclerosing Cholangitis

iUK-Health Economic Study on Patients With Primary Sclerosing Cholangitis Using Enhanced MRCP (MRCP+) (iUK-PSC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04015310
Recruitment Status : Not yet recruiting
First Posted : July 10, 2019
Last Update Posted : July 10, 2019
University of Birmingham
Information provided by (Responsible Party):
Perspectum Diagnostics Ltd

Brief Summary:
This is a health economic study on using quantitative magnetic resonance imaging in biliary disease. It is an observational study aiming to recruit 40 patients with Primary Sclerosing Cholangitis (PSC) in 12 months. The aim of the study is to assess the effect of result of enhanced Magnetic Resonance Cholangiopancreatography (MRCP+) on the physicians' diagnosis and/or plans for patients with suspected or confirmed PSC, compared with usual standard of care. This study also aims to identify the cost-effectiveness of adding MRCP+ to the standard care pathway.

Condition or disease Intervention/treatment
Primary Sclerosing Cholangitis PSC Device: Quantitative Multi parametric MRI and enhanced MRCP

Detailed Description:

Primary sclerosing cholangitis (PSC) is the greatest unmet need in modern liver medicine. There continue to be no direct bio-markers for the diagnosis and monitoring of biliary diseases such as PSC, constituting a major barrier to drug development and to poor patient outcomes. This project aims to validate an imaging platform, enhanced Magnetic Resonance Cholangiopancreatography, MRCP+, to improve the standard of care for patients by generating the real-world evidence needed to support clinical adoption.

Biliary diseases significantly increase the likelihood of developing sclerosing cholangitis (SC), causing major morbidity and mortality. Sclerosing cholangitis, a chronic inflammatory cholestatic condition, is exemplified by the primary idiopathic autoimmune condition PSC. In the absence of effective therapies, hindered by a lack of measurable trial endpoints (bio-markers), liver transplantation is the only life-extending intervention, with PSC accounting for 15% of all European liver transplantations. Furthermore, biliary complications occur in 5-32% of all liver transplantations. MRCP+ has the potential to significantly improve the outlook for patients.

At present, diagnosis requires cholangiopancreatography, either magnetic resonance (MRCP) or endoscopic retrograde (ERCP). The current standard ERCP is expensive, invasive, and associated with a high risk of morbidity. MRCP is less invasive and cheaper. However, both result in inconsistent qualitative interpretations. MRCP+ is the first device to enable direct quantitative measurement of biliary disease and addresses both European and US Liver society (EASL and AASLD) concerns that early changes of PSC are missed by MRCP, necessitating adequate visualisation and quantitative assessment.

MRCP+ both enhances MRCP images and yields advanced quantitative biliary measures. Initial experience shows significant clinical potential. This project will provide substantive evidence for clinical adoption via a real-world study including heath economics to evaluate the cost-effectiveness and impact on the clinical care pathway.

To achieve this, 40 patients were recruited from the University Hospitals Birmingham (UHB) who are attending the centre for either a review or diagnosis of PSC. The patients will follow their usual care pathway, being seen by the consultant who will document their care plan. Following this appointment, and their consent, they will be asked to undergo a non-invasive, pain-free Magnetic Resonance Imaging (MRI) scan. MRCP+ reports generated from these scans will be returned to the consultant who will review the documented standard care treatment plan and ascertain whether any amendments would have been made in light of these further quantitative metrics gained from MRI.

The study team alongside the Oxford Academic Health Science Network (OAHSN), will use the clinical data generated by the 40 patients and create a health economic model, which can be used to generate a business case for adoption, an impact case study for dissemination across the network of 15 centres in the Academic Health Science Networks (AHSN) and contribute to a submission for Human Tissue Authority (HTA) as part of the evidence required to gain health technology adoption via the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) route.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Quantitative Magnetic Resonance Imaging in Biliary Disease: Health Economics Study
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : August 1, 2020
Estimated Study Completion Date : October 1, 2020

Group/Cohort Intervention/treatment
PSC patients attending outpatient
Primary sclerosing cholangitis, as defined by EASL and AASLD guidelines.
Device: Quantitative Multi parametric MRI and enhanced MRCP
Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care

Primary Outcome Measures :
  1. quantitative measurements using Enhance MRCP (MRCP+) and Physicians' decision making [ Time Frame: 8 months ]
    To assess the effect of quantitative data from MRCP+ results on a physicians' diagnosis and/or plans for care of patients with suspected or confirmed PSC compared with usual standard of care.

Secondary Outcome Measures :
  1. Cost effectiveness of using enhanced MRCP (MRCP+) for diagnosis and monitoring of PSC patients [ Time Frame: 12 months ]
    To quantify the potential reduction in patient management costs by reducing unnecessary appointments in secondary care by using MRCP+ technology quantitative reports in diagnosis and monitoring of PSC patients more accurately.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
40 adult participants will be recruited who are over the age of 18 and are attending a hepatology appointment at UHB and are either being investigated for PSC or have confirmed PSC.

Inclusion Criteria:

  • Adult patients aged 18 years or over
  • Patient due to attend the hepatology clinic for PSC diagnostics/review
  • Participant is willing and able to give informed consent

Exclusion Criteria:

  • The participants may not enter the study if they have any contraindication to magnetic resonance imaging (including pregnancy, extensive tattoos, pacemaker, shrapnel injury, severe claustrophobia).
  • Any other cause, including a significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04015310

Layout table for location contacts
Contact: Marc Goldfinger, PhD 004401865655327
Contact: Soubera Rymell, Soubera 004401865655327

Sponsors and Collaborators
Perspectum Diagnostics Ltd
University of Birmingham

Layout table for additonal information
Responsible Party: Perspectum Diagnostics Ltd Identifier: NCT04015310     History of Changes
Other Study ID Numbers: EC-156
First Posted: July 10, 2019    Key Record Dates
Last Update Posted: July 10, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Keywords provided by Perspectum Diagnostics Ltd:
Health economic
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangitis, Sclerosing
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases